Compare BCYC & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCYC | ISD |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.4M | 486.1M |
| IPO Year | 2019 | N/A |
| Metric | BCYC | ISD |
|---|---|---|
| Price | $5.36 | $14.70 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $19.10 | N/A |
| AVG Volume (30 Days) | ★ 376.3K | 127.1K |
| Earning Date | 02-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.69% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.27 | $10.98 |
| 52 Week High | $13.11 | $13.17 |
| Indicator | BCYC | ISD |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 54.18 |
| Support Level | $5.27 | $14.51 |
| Resistance Level | $5.95 | $14.72 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 6.00 | 66.67 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.